Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Sen. Hatch on path to re-election; Senate passes FDA Safety and Innovation Act; DSM petitions FDA for folic acid fortification of masa flour; Nutrition 21 returns under new management; ZO Skin Health defends trademarks; more news In Brief.

You may also be interested in...



InterHealth Responsible For Zychrome Claims By Manufacturers – NAD

NAD recommends InterHealth discontinue superiority claims comparing its Zychrome chromium dinicocysteinate ingredient to Nutrition 21’s chromium picolinate product, Chromax. The decision tracks FTC’s position of holding branded ingredient suppliers responsible for claims made by their customers.

InterHealth Responsible For Zychrome Claims By Manufacturers – NAD

NAD recommends InterHealth discontinue superiority claims comparing its Zychrome chromium dinicocysteinate ingredient to Nutrition 21’s chromium picolinate product, Chromax. The decision tracks FTC’s position of holding branded ingredient suppliers responsible for claims made by their customers.

Harkin Exit Intensifies Industry Need To Bolster Supplement Caucus

One of DSHEA’s chief authors, Tom Harkin will retire from the Senate after 2014, pressuring supplement industry leaders to identify the next generation of congressional supporters. CRN’s Steve Mister says it will not be possible to replace the duo of Harkin and Orrin Hatch, who is retiring after 2018.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel